Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in Severe Alopecia Areata
NCT06444451Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of amlitelimab in alopecia areata, sponsored by Sanofi. Started Jun 2024; status: terminated.
02
Drugs
amlitelimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06444451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444451.